Company news
Vistagen Therapeutics, Inc. news in 2024
Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
November 6, 2024
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
September 22, 2024
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
August 12, 2024
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
July 8, 2024
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
June 26, 2024
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
June 10, 2024
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
April 24, 2024
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
March 31, 2024
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
February 12, 2024
Calls in 2024
- Vistagen Therapeutics (NASDAQ:VTGN) Q2 2025 Earnings Call
Nov 7, 2024
Transcript - Vistagen Therapeutics (NASDAQ:VTGN) Q1 2025 Earnings Call
Aug 13, 2024
Transcript - Vistagen Therapeutics (NASDAQ:VTGN) Q4 2024 Earnings Call
Jun 11, 2024
Transcript - Vistagen Therapeutics (NASDAQ:VTGN) Q3 2024 Earnings Call
Feb 13, 2024
Transcript
Decks in 2024
- Investor Presentation (December 2024)
Investor deck · 58 slides · Dec 6, 2024
- Investor Presentation (January 2024)
Investor deck · 62 slides · Jan 9, 2024